Cargando…

Metabolomic biomarkers for hepatocellular carcinoma: A systematic review

Background: Hepatocellular carcinoma (HCC) is a highly malignant cancer which lack of effective diagnosis and prognosis biomarkers, therefore surging studies focused on the metabolite candidates for HCC. The current study was designed to systematically review the metabolic studies for HCC, summarize...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Ningning, Yu, Fatao, Yu, Feng, Feng, Yuling, Zhu, Xiaolin, Xie, Zhihui, Zhai, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772637/
https://www.ncbi.nlm.nih.gov/pubmed/35060504
http://dx.doi.org/10.1097/MD.0000000000028510
_version_ 1784635888809017344
author Feng, Ningning
Yu, Fatao
Yu, Feng
Feng, Yuling
Zhu, Xiaolin
Xie, Zhihui
Zhai, Yi
author_facet Feng, Ningning
Yu, Fatao
Yu, Feng
Feng, Yuling
Zhu, Xiaolin
Xie, Zhihui
Zhai, Yi
author_sort Feng, Ningning
collection PubMed
description Background: Hepatocellular carcinoma (HCC) is a highly malignant cancer which lack of effective diagnosis and prognosis biomarkers, therefore surging studies focused on the metabolite candidates for HCC. The current study was designed to systematically review the metabolic studies for HCC, summarize the current available evidence and provide implication for further studies within this area. By systematically screening Pubmed and Embase, and eligibility assessment, we eventually included 55 pieces of studies. After summarized their characteristics, we reviewed them by 3 parts, regarding to the different biofluid they carried out the experiments. By collecting the candidates from all the included studies, we carried out pathway enrichment to see the representative of the reported candidates, as expected the pathway consistent with the current knowledge of HCC. Next, we conduct quality assessment on the included studies. Only 36% of the current evidence grouped as high quality, indicating the quality of metabolic studies needs further improvement.
format Online
Article
Text
id pubmed-8772637
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-87726372022-01-21 Metabolomic biomarkers for hepatocellular carcinoma: A systematic review Feng, Ningning Yu, Fatao Yu, Feng Feng, Yuling Zhu, Xiaolin Xie, Zhihui Zhai, Yi Medicine (Baltimore) 4500 Background: Hepatocellular carcinoma (HCC) is a highly malignant cancer which lack of effective diagnosis and prognosis biomarkers, therefore surging studies focused on the metabolite candidates for HCC. The current study was designed to systematically review the metabolic studies for HCC, summarize the current available evidence and provide implication for further studies within this area. By systematically screening Pubmed and Embase, and eligibility assessment, we eventually included 55 pieces of studies. After summarized their characteristics, we reviewed them by 3 parts, regarding to the different biofluid they carried out the experiments. By collecting the candidates from all the included studies, we carried out pathway enrichment to see the representative of the reported candidates, as expected the pathway consistent with the current knowledge of HCC. Next, we conduct quality assessment on the included studies. Only 36% of the current evidence grouped as high quality, indicating the quality of metabolic studies needs further improvement. Lippincott Williams & Wilkins 2022-01-21 /pmc/articles/PMC8772637/ /pubmed/35060504 http://dx.doi.org/10.1097/MD.0000000000028510 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 4500
Feng, Ningning
Yu, Fatao
Yu, Feng
Feng, Yuling
Zhu, Xiaolin
Xie, Zhihui
Zhai, Yi
Metabolomic biomarkers for hepatocellular carcinoma: A systematic review
title Metabolomic biomarkers for hepatocellular carcinoma: A systematic review
title_full Metabolomic biomarkers for hepatocellular carcinoma: A systematic review
title_fullStr Metabolomic biomarkers for hepatocellular carcinoma: A systematic review
title_full_unstemmed Metabolomic biomarkers for hepatocellular carcinoma: A systematic review
title_short Metabolomic biomarkers for hepatocellular carcinoma: A systematic review
title_sort metabolomic biomarkers for hepatocellular carcinoma: a systematic review
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772637/
https://www.ncbi.nlm.nih.gov/pubmed/35060504
http://dx.doi.org/10.1097/MD.0000000000028510
work_keys_str_mv AT fengningning metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview
AT yufatao metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview
AT yufeng metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview
AT fengyuling metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview
AT zhuxiaolin metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview
AT xiezhihui metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview
AT zhaiyi metabolomicbiomarkersforhepatocellularcarcinomaasystematicreview